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A B S T R A C T
In forensic toxicology, alternative matrices to blood are useful in case of limited, unavailable or unusable
blood sample, suspected postmortem redistribution or long drug intake-to-sampling interval. The
present article provides an update on the state of knowledge for the use of bile in forensic toxicology,
through a review of the Medline literature from 1970 to May 2015. Bile physiology and technical aspects
of analysis (sampling, storage, sample preparation and analytical methods) are reported, to highlight
speciﬁcities and consequences from an analytical and interpretative point of view. A table summarizes
cause of death and quantiﬁcation in bile and blood of 133 compounds from more than 200 case reports,
providing a useful tool for forensic physicians and toxicologists involved in interpreting bile analysis.
Qualitative and quantitative interpretation is discussed. As bile/blood concentration ratios are high for
numerous molecules or metabolites, bile is a matrix of choice for screening when blood concentrations
are low or non-detectable: e.g., cases of weak exposure or long intake-to-death interval. Quantitative
applications have been little investigated, but small molecules with low bile/blood concentration ratios
seem to be good candidates for quantitative bile-based interpretation. Further experimental data on the
mechanism and properties of biliary extraction of xenobiotics of forensic interest are required to
improve quantitative interpretation.
 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and hepatic artery blood blends in the liver sinusoids, which drain into the central
vein. Bile is secreted by hepatocytes, fringing the sinusoids, in the biliary canaliculi
before entering the biliary ducts.1. Introduction
Bile is a complex greenish-yellow liquid secreted by the
hepatocytes of the liver. Outside of mealtimes, it is stored in the
gallbladder, and released into the duodenum during digestion
notably to facilitate lipid absorption by the intestine [1] and
protect the intestinal mucosa against gastric acid [2]. It is also a
medium of excretion of endogenous substances such as bilirubin, a
breakdown product of hemoglobin, or excess cholesterol and of
exogenous substances such as heavy metals and drugs [3]. Thus,
bile contributes, along with metabolism, to liver puriﬁcation and is
an elimination pathway for xenobiotics which, once excreted into
the bile, are eliminated via the feces. The biliary system is involved
in the ﬁrst-pass effect of the liver, which consists in the
metabolism or excretion of certain xenobiotics absorbed from
the digestive system before they can reach the systemic blood
circulation. Enterohepatic circulation is possible for some endoge-
nous (e.g. bile salts) or exogenous molecules (morphine, colchicine,
etc.) that are excreted into the bile but then reabsorbed in the
intestine, to enter the general circulation or else be excreted again
[4–6].
Bile has been studied as a postmortem matrix for screening for
human chorionic gonadotropin (bhCG) [7], human immunodeﬁ-
ciency virus (HIV) [8], insulin [9–11] or blood group [12]. Biliary
excretion of metals and its role in their potential toxicity have also
been a focus of studies [1,13–15]. Bile is especially an additional
autopsy sample for toxicologic analysis alongside other matrices
(central blood, peripheral blood, stomach contents, etc.) or in the
absence of analyzable blood. It is easy to sample postmortem from
the gallbladder and tends to show high levels of xenobiotics, so
that it is often seen as an interesting matrix for wide-scale
screening [16,17].
Understanding, assessing and possibly anticipating a molecu-
le’s behavior in terms of biliary elimination is very useful for the
development of new treatments as well as in forensics to help
interpret bile results. Biliary excretion, however, is complex and
difﬁcult to study. In vivo analysis obviously runs up against
problems of access [3,18]. Studies are therefore often performed in
animal models or in vitro (perfused liver, hepatocyte culture,
hepatocyte membrane reconstitution), entailing issues of extrap-
olation. In vivo sampling is, nevertheless, feasible via T-tubes ﬁtted
in cholecystectomy patients [19], but such studies are biased by
the presence of hepatobiliary pathology. Postmortem data involve
the problem of wide variability in forensic populations and the lack
of information regarding xenobiotic intake.
The present review has two objectives: (1) to provide an
update on biliary physiology and xenobiotic excretion for forensic
toxicology purposes; and (2) to serve as a practical tool at all levels
of toxicological bile analysis: sampling, storage, analysis and,
above all, interpretation. A Medline search was performed with
the key-word ‘‘bile’’ combined to ‘‘forensic’’, ‘‘medicolegal’’,
‘‘quantiﬁcation’’, ‘‘postmortem’’, ‘‘post mortem’’, ‘‘autopsy’’ and‘‘chromatography + drug’’ (updated May 2015). The search was
limited to the organic molecules most frequently encountered in
routine forensic toxicology (some medical drugs, drugs of abuse
and ethanol) and to publications after 1970.
2. Physiology
2.1. Anatomy of the liver and biliary system
The liver has a rich vascular system, comprising the hepatic
artery, supplying highly oxygenated blood, and the portal vein,
transporting nutrients from the digestive system. These vessels
ramify in the liver lobules, which are functional units (Fig. 1), and
join in the sinusoids draining into the central vein and then the
systemic circulation via the hepatic veins [19]. With this double
input, the liver puriﬁes not only arterial blood, as do the kidneys,
but also portal vein blood, eliminating toxins absorbed by the
digestive system before they reach the general circulation: this is
known as the ﬁrst-pass liver effect. The liver sinusoids are fringed
with hepatocytes, secreting bile into biliary canaliculi formed
between two adjacent cells whose adjoining apical membranes are
sealed by tight junctions [1]. These canaliculi are drained in
ductules and then biliary canals which progressively join together
in a complex network of intra- then extra-hepatic ducts (the biliary
tree), to form the common hepatic duct. This then divides into the
common bile duct or ductus choledochus, on the one hand,
releasing bile into the duodenum via the sphincter of Oddi, and the
cystic duct, on the other, feeding into the gallbladder where bile is
Fig. 2. Structure of the biliary tree.
Adapted from [18] with permission.
Table 1
Main components of canalicular and gallbladder bile [22].
Canalicular bile Gallbladder bile
Water 97.5 g/dL 92 g/dL
Bile salts 1.1 g/dL 6 g/dL
Bilirubin 0.04 g/dL 0.3 g/dL
Cholesterol 0.1 g/dL 0.3–0.9 g/dL
Fatty acids 0.12 g/dL 0.3–1.2 g/dL
Lecithin 0.04 g/dL 0.3 g/dL
Na+ 145 mEq/L 130 mEq/L
K+ 5 mEq/L 12 mEq/L
Ca++ 5 mEq/L 23 mEq/L
Cl 100 mEq/L 25 mEq/L
HCO3
 28 mEq/L 10 mEq/L
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about 50 mL capacity [21,22] fulﬁlling two main functions:
concentrating bile, and storing it for release at the right moment
during digestion. The gallbladder wall comprises a serous external
layer, an intermediate muscular layer providing motility, and an
epithelial layer of cells able to absorb water and various
electrolytes and cells secreting a mucous protection against bile
salts [23].
2.2. Bile formation
Hepatocytes secrete what is known as hepatic or canalicular
bile. Bile ﬂow results from complex processes of secretion (bile
salts, phospholipids, vitamin D, etc.) and of excretion of substances
to be eliminated (bilirubin, xenobiotics, etc.). Active transport of
solutes, including bile salts (bile-salt-dependent bile ﬂow) and
other osmotically active compounds (bile-salt-independent bile
ﬂow), induces an osmotic gradient which in turn induces ﬂow of
water and electrolytes [1,24,25]. The bile is then modiﬁed by the
bile duct wall cells (cholangiocytes), by absorption/secretion
adjusting bile ﬂow, bile-salts concentration and alkalinity [20].
The volume of bile produced by the liver is about 600 mL to 1 L per
day, and is regulated by several signals such hormone release
following a meal (secretin) and circulating bile salt level [1,18,24].
Outside of mealtimes, the sphincter of Oddi is closed and bile
passes into the gallbladder, where it is stored and modiﬁed by
reabsorption of water and electrolytes, resulting in gallbladder
bile, which is 5–20 times as concentrated as canalicular bile
[21,22]. In reaction to neural and hormonal (cholecystokinin)
stimuli triggered by feeding, the gallbladder is partially emptied by
muscle contractions and the bile is released into the intestine,
where it facilitates absorption, notably of lipid and lipophilic
substances. Gallbladder emptying is proportional to the lipid
content of the meal [2]. During the meal, canalicular bile is
delivered directly to the intestine but is stored in the gallbladder
between two meals and during fasting [22,24]. Secretion is altered
by liver pathology and by speciﬁc biliary pathway pathologies such
as cholestasis or cholecystitis, especially those secondary to biliary
tract lithiasis or cancer [5,23,26].
2.3. Bile composition
Canalicular bile is a yellow liquid, while gallbladder bile is
thicker and deep yellow to green in color. Both are slightly alkaline.
Bile is mainly constituted of water (95%) with compounds in
solution or in suspension: electrolytes (sodium, potassium,
calcium, chloride, bicarbonate), bile salts (particularly cholic andchenodeoxycholic acid), phospholipids (mainly lecithin), choles-
terol, bile pigments (bilirubin, porphyrin, etc.) and proteins
(immunoglobulins, albumin, etc.) [1]. Bile may thus be deﬁned
as a complex alkaline aqueous medium containing most of the
solutes found in blood and micelles formed by bile salts able to
contain the most lipophilic compounds. Table 1 presents the main
components of canalicular and gallbladder bile.
2.4. Principle of biliary excretion of xenobiotics
Biliary excretion is one of the organism’s means of eliminating
exogenous substances [5], thereby contributing, along with
metabolism, to the puriﬁcation function of the liver. Biliary
excretion of xenobiotics by hepatocytes requires two cell
membranes to be crossed: the basolateral membrane of hepato-
cytes at the blood sinusoids side, and the apical membrane forming
the biliary canaliculus (Fig. 3). Crossing of molecules, whether or
not bound to plasma protein, from the sinusoid to the hepatocytic
extracellular space, known as the space of Disse, is unrestricted,
due to the fenestration of the epithelial cells (sinusoidal cells) and
the lack of basal membrane in this type of blood capillary [27].
From the space of Disse, only the free fraction of the substance can
penetrate the hepatocyte, by simple diffusion and/or active
transfer; the molecule may then bind to intracellular protein,
excrete back into the blood-ﬂow or in the biliary canaliculi, either
unmodiﬁed or in the form of metabolites. For some compounds,
such as plasma proteins, other biliary excretion mechanisms have
been described, such as endocytosis-exocytosis [24] or diffusion
through the inter-hepatocyte tight junctions, which does not
require cell penetration (para-cellular route) [1]. As mentioned
above, the bile secreted by the hepatocyte is drained into the
biliary system and then released into the duodenum, most of its
components being eliminated in feces. Certain molecules, howev-
er, may be reabsorbed in the intestine; either in the form in which
they were secreted (parent or metabolite) or after being
metabolized by the intestinal ﬂora, as in the case of glucuronide
conjugates, where the parent molecule is reabsorbed following the
action of intestinal glucuronidases. In molecules of forensic
interest, such as morphine, colchicine, lorazepam or digoxin,
enterohepatic cycle is well-known and results in systemic
recirculation that may give rise to several plasma concentration
peaks and lengthened elimination half-life [4,5].
2.5. Role of transporters
Xenobiotic penetration in hepatocytes may be by passive
diffusion or by active transfer via a transporter; generally, the
higher the molecular weight and/or hydrophilicity of the
compound, the more its diffusion depends on active transport
[18]. Due to the importance of the liver in metabolism and
elimination, hepatocytes express numerous transporters able to
Fig. 3. Xenobiotic exchanges in the hepatocyte. Adapted from [278] with
permission. The xenobiotic, circulating in the sinusoids, freely enters the space
of Disse by intercellular gaps between endothelial cells, fenestrations, and lack of
complete basal lamina. Then it penetrates the hepatocyte by simple diffusion and/
or active transfer. Within the hepatocyte, it may bind to intracellular protein,
excreted into bile or transferred back to the blood in parent or metabolite form.
Fig. 4. Membrane transporters that determine the uptake and excretion of organic sol
Uptake from blood (basolateral membrane) [1]:-. NTCP (sodium taurocholate cotranspo
anion transporting polypeptides): broad substrate carriers of large hydrophobic anions a
afﬁnity for hydrophilic anions.-. OCT (organic cation transporters): sodium independen
Excretion in bile (canalicular membrane) [1]:-. MDR1 (multidrug resistance 1, P-glycopro
afﬁnity for phospholipids.-. MRP2 (multidrug resistance associated protein 2, previously
anions or amphipathic solutes such as conjugated metabolite.-. BRCP (breast cancer res
BSEP (bile salt export pump): afﬁnity for bile salt.-. MATE1 (multidrug and toxin extrusio
et 2 (ABCG5 and ABCG8 gene): afﬁnity for cholesterol and other sterols.-. Chloride/bic
F. Be´valot et al. / Forensic Science International 259 (2016) 133–154136bind circulating molecules. They comprise mainly two types of
transmembrane protein: inﬂux pumps of the SLC (SoLute Carrier)
superfamily, and efﬂux pumps of the ABC (ATP Binding Cassette)
superfamily [1]. Unlike passive diffusion, active transport may be
limited by saturation if molecule concentration exceeds trans-
porter capacity, by competition with other compounds or by
inhibition by speciﬁc substrates [28].
Biliary excretion mainly depends on active transport of solutes
essential to the composition and ﬂow of bile. Concentrations that
may be 10 to 100-fold higher than in blood require diffusion
against the concentration gradient: active ATP-dependent trans-
port is necessary [19,24,29,30] and passive diffusion may be
considered negligible. Fig. 4 shows the main transporters found on
hepatocyte membranes and their corresponding substrates.
2.6. Characteristics of bile-excreted molecules
As bile is difﬁcult to analyze at the various stages of its formation,
data for the characteristics of bile-excreted molecules are sparse
and often derived from animal, in vitro models or in vivo in subjects
with biliary pathology. Nevertheless, certain interesting facts can be
highlighted. Molecules found in bile, whether endogenous or
exogenous, can be divided into two groups according to plasma/bile
concentration ratio: those with ratios less than or close to 1, and
those with ratios much greater than 1 [3,16].
Ratios less than or close to 1 may correspond to poor hepatocyte
absorption or to poor excretion into the biliary canaliculi (e.g.,
passive diffusion only) and/or subsequent reabsorption in the bile
ducts or gallbladder [31] (as demonstrated for glucose [1] and
methylmercury [32]). Moreover, certain strongly metabolized
molecules have low bile clearance in their unmodiﬁed form
whereas their metabolites may show non-negligible biliary
excretion (morphine glucuronides [5]). Inter-subject metabolic
differences, whether pathologic or genetic, may thus affect bile
clearance of xenobiotics [26,33,34].
Molecules with elevated bile excretion have been the focus of
several studies. In the 1970s, a molecular weight threshold was
determined below which compounds are unlikely to be excreted inutes in hepatocytes.
rting polypeptide): primary carrier for conjugated bile salt uptake.-. OATP (organic
nd amphipathic organic solutes such as bile salt.-. OAT (organic anion transporter):
t uptake of small organic cations.
tein): ATP dependent excretion of organic cations.-. MDR3 (multidrug resistance 3):
 known as multispeciﬁc organic anion transporter MOAT): afﬁnity for multivalent
istance protein): substrate overlap with MRP2, multispeciﬁc anions transporters.-.
n transporter): organic cation/H+ exchanger such as cationic xenobiotic.-. Steroline 1
arbonate exchanger.-. Aquaporine: water diffusion.
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[3,5,35,36]. Lipophilicity was also identiﬁed as a determining
factor. A study of endogenous and exogenous steroid hormones
tended to show that more apolar compounds (e.g., progesterone)
showed greater bile excretion than more polar compounds (e.g.,
hydrocortisone) [5]. A similar tendency was also found for cations
such as triethylmethylammonium, tripropylmethylammonium,
thiazinium, etc. [5]. A rough-and-ready idea thus came to be
adopted that small polar molecules are eliminated via the kidneys
and ‘‘the others’’ via biliary/fecal routes. More recent studies
showed that molecular weight and lipophilicity are not enough to
predict bile concentrations. More complex QSPKR (quantitative
structure-pharmacokinetic parameters relationship) or PBPK
(physiologically based pharmacokinetic) models were described,
based, for example, on physicochemical properties: steric bulk,
permeability and solubility, and polarizability [29,35,36]. Another
determining factor in biliary excretion was reported to be afﬁnity
for transporters located on hepatocyte sinusoid and canaliculus
membranes (Fig. 4). As mentioned above, active transport plays a
preponderant role. Transporter substrate and cell expression are
increasingly the focus of studies. These studies, however, mainly
concern endogenous substrates, inhibitors involved in drug
interactions or certain therapeutic classes such as anticancer,
antibiotic and antiviral [1,24,27,29,37], and few focused on
molecules of forensic interest. For example, glycoprotein P (P-gp
or MDR) has been the focus of many studies concerning its
functions [38,39] and role in biliary transport [1,25]. It is notably
involved in extracellular transport of endogenous and exogenous
organic cations [4] but only a few forensic compounds are
identiﬁed as its substrate (e.g., verapamil [1], digoxin [40], certain
benzodiazepines [41] and alkaloids [4]).
2.7. Postmortem evolution of bile
To the best of our knowledge, no data are available for the
postmortem evolution of bile and its availability at autopsy.
Availability may depend on how full the gallbladder is and thus on
time of death with respect to mealtime. Moreover, bile may be
subject to postmortem processes which could probably affect
composition: perivascular diffusion following gallbladder damage,
or dehydration. In the Forensic Medicine Institute of Lyon (France),
bile could be sampled in 85% of autopsies performed between 2010
and 2013 (personal data).
3. Bile analysis
3.1. Sampling and storage
During autopsy, bile can easily be collected by syringe
aspiration from the gallbladder, or by incision-compression if
the bile is too viscous [42]. The entire content or up to 10–15 mL
should be sampled [42–45]. The container should be adapted to the
volume, to avoid evaporation of volatile molecules in the head
space, oxidation or possible precipitation if a preservative agent is
used in overconcentration [46]. In case of cholecystectomy,
sampling is trickier, but can be performed directly in the common
bile duct [43]: the toxicologist should be informed of the sampling
site, given the differences in composition between liver and
gallbladder bile. Some authors recommend collecting bile ahead of
organ dissection, to avoid contamination both of the bile, notably
by stomach or intestine contents, and of the organs by the bile
[43,47]. For the same purpose, ligating the gallbladder ahead of
sampling is also recommended although the efﬁcacy of this
measure has not, to our knowledge, been assessed [45,46,48].
There have been few studies focusing on the stability of bile
samples according to storage conditions. To prevent hydrolysis ofglucuronide metabolites, the sample can be slightly acidiﬁed by
adding a buffer (e.g. ammonium acetate 1 M pH 4.0/5.5 or sodium
acetate 0.1 M pH 5) or acid (acetic or chlorhydric) at the moment of
sampling [49,50]. Melo et al. [51] used liquid chromatography
coupled to a ultraviolet (UV) detector to study the bile stability of
four benzodiazepines (lorazepam, estazolam, ketazolam and
chlordiazepoxide) up to 6 months at 80 8C, 20 8C, +4 8C and
+25 8C with or without addition of sodium ﬂuoride (NaF) as
preservative. Sampling with preservative, storage at 4 8C for a short
period and freezing for long-term storage were recommended, to
limit degradation of these benzodiazepines in bile. Chlordiazepox-
ide stability was better in bile than in blood, which the authors
attributed to bile being a relatively unfavorable environment for
the development of microorganisms. In the absence of speciﬁc data
on bile samples, guidelines for storage of speciﬁc molecules
obtained from other matrices are relevant.
3.2. Analytic procedures
3.2.1. Screening
Immunologic screening for certain groups of xenobiotics is
feasible in bile [52,53]. The immuno-analysis kit may, however,
require pre-treatment by solvent or protein precipitation [53] to
reduce viscosity and matrix interference. The Abbott TDx analyzer,
no longer on the market, was based on ﬂuorescence polarization
immuno-analysis (FPIA). It was assessed for opiate screening in
bile [54]: detection required adapting the protocol, initially
designed for blood, by increasing the dilution to reduce the
intensity of matrix ﬂuorescence; quantiﬁcation required using a
standard addition method, as the matrix effect varied from sample
to sample. Other immunologic techniques have been used to
screen for opiates [55,56], cocaine derivatives [57,58], acetamino-
phen [17] and alcohol [59] in bile.
The ﬁrst reported general unknown screening (GUS) for medical
drugs and narcotics speciﬁcally in bile consisted in liquid/solid
extraction after lyophilization associated to thin layer chromatogra-
phy [60]. The automated REMEDI (Rapid EMErgency Drug Identiﬁ-
cation) system, which is no longer on the market, was assessed for
GUS in a forensic context, in blood and alternative matrices including
bile [61]. Vanbinst et al. [17] described a screening method common
to blood, urine, bile and stomach contents, based on liquid/liquid
extraction (LLE) under acid and alkaline pH and extract analysis by
high performance liquid chromatography (HPLC) with diode array
detector (DAD) and gas chromatography (GC) coupled to mass
spectrometry (MS). For the same four matrices, Soriano et al. [62]
developed a targeted screening method, assessed for 25 molecules,
using solid phase extraction (SPE) coupled to GC/MS and GC with
nitrogen phosphorus detector (NPD), with special attention given to
the development of the extraction. Bevalot et al. [63] described an
SPE method with double elution as a basis for developing GUS or
targeted analyses in alternative matrices; it was validated for bile on
6 molecules of varied pharmacokinetic properties (morphine,
6-MAM, meprobamate, cyamemazine and caffeine) and assessed
on 12 others of forensic interest.
3.2.2. Speciﬁc assay methods
Pharmacokinetic studies require high reliability; therefore bile-
speciﬁc analytic procedures have been developed and validated
[49]. For example, analysis of cannabinoids and certain of their
conjugated metabolites was validated in bile for the study of biliary
excretion [64]. In forensic toxicology, a few analytic methods have
been adapted and/or validated speciﬁcally for quantiﬁcation in
bile; for example, the literature mentions assays for morphine
[65,66], cocaine [57], 4 benzodiazepines associated to citalopram
[67] and 5 combined molecules (morphine, 6-MAM, meprobamate,
cyamemazine and caffeine) [63].
F. Be´valot et al. / Forensic Science International 259 (2016) 133–154138Bile, however, entails certain analytic problems due to its
complex composition. It is an excretion medium for high-
concentration endogenous and exogenous compounds or phase-
1 metabolites structurally close to their parent molecule [49,68].
This may induce interferences affecting sensitivity and speciﬁcity,
especially when an insufﬁciently speciﬁc detector, such as by UV or
ﬂame ionization, is used [66]. In mass spectrometry, interferences
may not be visible but still induce a matrix effect reducing or
boosting the ion signal and impairing reliability [49]. Fabritius et al.
[64] reported 20–80% signal suppression in an LC/MSMS assay
method for various bile cannabinoids; however, the ion suppres-
sion effect did not impact the accuracy of the test. In contrast, Lauer
et al. [69] developed a colchicine quantiﬁcation method in matrices
collected and dried on ﬁlter paper (DBS: dried blood spot
technique). Successfully validated in blood and 8 other ﬂuids and
biological tissues, it did not enable reliable quantiﬁcation of
colchicine in bile due to a major matrix effect with 99.3% signal
suppression. Thus, this ﬁlter-paper method, consisting in a simple
methanol extraction, is an inadequate puriﬁcation technique for
the complexity of bile. The authors concluded by citing Skopp’s rule
[42] that it is better not to transfer methods validated on other
biological ﬂuids directly to bile. Sensitivity is not usually the focus
of bile analysis, as concentrations tend to be high [53,66,68], and it
is better to have an effective puriﬁcation technique, ensuring better
speciﬁcity and reliability even with a lower level of extraction.
Despite the above problems of bile analysis, the literature is rich
in case reports describing xenobiotic distribution in biological
matrices, including bile, in which the analytic technique is
transferred directly from that used for blood or adapted without
assessment. This may be suitable for a single case report aimed at
comparing concentrations between matrices and considering the
uncertainties relating to postmortem phenomena (redistribution,
stability, etc.) [49]. The standard addition method may provide a
good solution, taking account of the nature of the matrix, but
requires a sufﬁcient sample quantity [17]. To improve assay quality,
calibration in blank bile should be used with concentrations
adapted to bile, as well as an internal standard structurally close to
the analyte, such as a deuterated analog if available. For larger series,
Hoizey et al. [70] assessed the reliability of a method transferred to
another matrix by performing quality controls prepared by doping
matching blank matrix. Finally, for more systematic use or
pharmacokinetic study, validation should be performed following
current guidelines such as those of the Scientiﬁc Working Group for
Forensic Toxicology [71]. In the case of analytical assays intended
for several matrices, crossed validation is a satisfactory means of
ensuring reliability with a limited number of trials; it meets Food
and Drug Administration guidelines [72] and was applied for partial
validation of a bile analysis method based on a method entirely
validated in blood [69] or in bone marrow [63,67]. The validation
criteria for partial validation may include the following: selectivity,
limit of quantiﬁcation, range linearity, accuracy and intermediate
precision at several concentration levels.
3.2.3. Free and conjugated forms: hydrolysis procedures
Like blood or urine, bile can be hydrolyzed to quantify both free
and conjugated forms of molecules. Various enzymatic procedures
were described to estimate total morphine in bile: Patella vulgata
glucuronidase (3000–5000 U, overnight incubation at 55 8C) [66],
b-glucuronidase at pH 5.1 [73], Escherichia coli b-glucuronidase
(overnight incubation at 47 8C) [74]. Nakamura and Way [65] also
employed chemical hydrolysis to quantify free plus conjugated
morphine: bile samples were treated with 1 N sulfuric acid and
autoclaved for 15 min at 15 pounds. Free and conjugated forms of
benzodiazepines were evaluated in rat bile by St-Pierre and Pang
[75] by enzymatic hydrolysis (Helix pomatia b-glucuronidase,
500 U, at pH 5, incubation 24 h at 37 8C). These studies show thatclassical hydrolysis procedures can be employed with success on
bile samples.
4. Interpretation of bile analysis results
Bile concentrations are reported in many case reports, usually
alongside assays in others matrices and without discussion. There
are few large autopsy series or animal studies focusing on the
advantages and drawbacks of bile as study matrix in forensic
toxicology.
4.1. Case reports
Table 2 presents the case reports retrieved in the literature
referenced in Medline which report bile concentrations, with the
number of cases, cause of death and blood concentration. Bile/
blood concentration ratios were calculated from these data. It is
intended as a working tool for toxicologists analyzing and
interpreting particular molecules. The higher concentrations in
bile than blood have often been highlighted. This can be objectiﬁed
from the numerous case reports in Table 2, since more than 80% of
the 135 compounds presented bile/blood concentration ratios
clearly greater than 1. Many of them are of interest forensic
toxicology, such as narcotics, toxic principles of plant origin,
psychotropic drugs, etc.
4.2. Qualitative interest
The higher concentrations in bile as compared to blood have
often been highlighted. The extent of bile excretion can be seen
from signiﬁcant autopsy series for most narcotics: opioids
(morphine and codeine) [66,73], fentanyl [76], oxycodone [77],
buprenorphine [78], amphetamine derivatives [79], cocaine
derivatives [16,57] and cannabinoids [80].
Bile excretion of morphine and morphine glucuronide con-
jugates has been widely described and the existence of enter-
ohepatic circulation [4,5,19,81] may induce prolonged presence in
blood and bile. Buprenorphine showed massive bile excretion as
parent molecule (mean bile/blood ratio of 9638, n = 12) or as the
metabolite norbubrenorphine [78]. For cannabis, the bile/blood
concentration ratio is low for D-9-te´trahydrocannabinol (THC) but
higher for its metabolites, including 11-Nor-9-carboxy-THC (THC-
COOH), 11-hydroxy-THC (11OH-THC), and the THC and THC-COOH
glucuronides [64,82]. In a series of 50 road accident deaths
involving cannabis [80], the bile/cardiac blood concentration ratio
of total THCCOOH (free + glucuronide) ranged from 17.2 to 888;
THC was not analyzed. Like morphine, the presence in gallbladder
of THCCOOH glucuronides, liable to be hydrolyzed by intestinal
ﬂora and reabsorbed, suggested enterohepatic recirculation that
could contribute to the long detection time of cannabinoids [3].
Two studies compared bile and blood concentrations for cocaine
derivatives. The ﬁrst, using radio-immunologic assay, reported
ratios ranging from 2.15 to 107.53 (mean = 30.79) over 20 cases
[57]. The second, in a series of 50 cases (analytic method not
speciﬁed), found ratios between 5 and 7 for cocaine and its
metabolites [16]. Bile excretion levels are lower for amphetamine
derivatives. Liu et al. [79] reported a bile/blood ratio of 0.64 to 9.8
for 3,4-methylenedioxy-methamphetamine (MDMA) (n = 11).
Vanbinst et al. [17] reported ratios of 1.19 for amphetamine
(n = 1) and 1.59 for MDMA (n = 2); these were among the lowest
ratios in this study of 36 medicines or drugs of abuse. In this study,
drugs of abuse (cocaine, 2-ethylidine-1,5-dimethyl-3,3-diphenyl-
pyrrolidine (EDDP), MDMA, methadone, morphine and codeine)
were detected in bile but not blood in 36.3% of cases (n = 44).
Agarwal and Lemos [16] likewise found that in several cases
cocaethylene was detectable only in bile.
Table 2
Case reports providing bile concentrations: substance name, number of cases reported (n), cause of death, blood concentrations (peripheral and/or cardiac, ‘‘blood’’ if not speciﬁed), bile concentration.






Peripheral blood Cardiac blood
25I-NBOMe 1 Fatal intoxication involving
25I-NBOMe
405pg/mL 410pg/mL 10.9ng/g #/# [111]
3,5-dimethoxyphenol 1 Fatal poisoning by Taxus 217ng/mL 100ng/mL 175ng/mL 0.81/1.8 [112]
4-MTAa 1 Overdose fatality involving 4-MTA
and MDMAa
5.49mg/L 7.60mg/L 36.4mg/L 6.6/4.8 [113]
6-MAMa 1 Multiple drug intoxication Blood: 0.93ng/mL ND – [114]
Acepromazine 1 Suicide by acepromazine
intoxication
Chest cavity blood: 0.6mg/mL 6.5mg/mL 10 [115]
Acepromazine 1 Suicide by acute zolpidem
overdose
Blood: 2.4mg/L 1.03mg/L 0.43 [116]




Thoracic: 57mg/L 73mg/L 1.2/1.3 [117]
Acetaminophen 3 Suicidal poisoning by co-proxamol 414mg/L 384mg/L 668mg/L 1.6/1.7 [118]
261mg/L 345mg/L 598mg/L 2.3/1.7
184mg/L 178mg/L 676mg/L 3.7/3.8
Aconitine 2 Suicidal Aconitum poisoning 10.3mg/L 14.9mg/L 139mg/L 14/9.3 [119]
15.4mg/L 33.7mg/L 240mg/L 16/7.1
Aconitine 1 Suicide by ingestion of aconite Serum: 1.1ng/mL 6.3ng/g # [120]
AH-7921a 1 Accidental opioid intoxication 9.1mg/L 3.9mg/L 17mg/L 1.9/4.4 [121]
Alimemazine 1 Fatal intoxication involving
alimemazine
Blood: 6.52mg/mL 4.44mg/mL 0.68 [122]
Alpha-methylfentanyl 1 Overdose by alpha-
methylfentanyl
Blood: 3.1ng/mL 6.4ng/mL 2.0 [123]
Alprazolam 1 Suicide by acute alprazolam
overdose
2.3mg/L 2.1mg/L 2.8mg/L 1.2/1.3 [124]
Amitriptyline 1 Fatal self-poisoning involving
amitriptyline
Blood: 0.82mg/L 8.01mg/L 9.8 [125]








Amoxapine 3 Suicide by amoxapine overdose Blood: 11.5mg/L 1264.5mg/L 110 [127]
Blood: 2.80mg/L 69.1mg/L 25
Blood: 0.89mg/L 14.30mg/L 16
Amoxapine 2 Suicide by multiple drug
intoxication
Blood: 182.2mg/L 6111mg/L 3.4 [128]
Blood: 6.70.9mg/L ND –
Amphetamine 1 Suicide by methamphetamine
overdose
0.74mg/L – 0.72mg/L 1.0/– [129]
Atomoxetine 2 –Arrhythmogenic right ventricular
dysplasia
0.33mg/L 0.65mg/L 1.0mg/L 3.0/1.5 [130]
–Suicide by venlafaxine and
atomoxetine overdose
5.4mg/L 8.3mg/L 33mg/L 6.4/1.2
Brucine 1 Suicide by brucine overdose 1.51mg/mL – 9.94mg/mL 6.6/– [131]
Buﬂomedil 1 Fatal intoxication involving
buﬂomedil
– 24.5mg/mL 39.1mg/mL –/1.6 [132]
Buformin 1 Lactic acidosis Serum: 3.2mg/L 6.3mg/L 2.0 [133]
Buprenorphine 1 Suicide by buprenorphine
intoxication
Blood: 3.3mg/L 2035mg/L 616 [134]
Buprenorphine 13 Fatal intoxication involving
buprenorphine
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Bupropion 1 Fatal intoxication by bupropion
and ethanol
Subclavian: 6.2mg/L – 1.4mg/L 0.23/– [136]
Caffeine 4 –Suicide by overdose Blood: 147.0mg/L 64.3mg/L 0.44 [137]
–Suicide by overdose Blood: 343.9mg/L 263.2mg/L 0.77
–Suicide by overdose Blood: 251.0mg/L 312.0mg/L 1.2
–Accidental Fatal overdose Blood: 184.1mg/L 200.2mg/L 1.1
Carbamazepine 1 Multiple drug intoxication Blood: 79mg/L 69mg/L 0.87 [138]
Chlorprothixene 1 Fatal intoxication involving
chlorprothixene
Blood: 0.10mg/L 3.9mg/L 39 [139]
Citalopram 7 –Fatal intoxication involving
citalopram
0.8mg/L – 6.0mg/L 7.5/– [140]
–Multiple drug intoxication 0.4mg/L (0.2–0.7) – 2.77mg/L (0.8–4.3) 6.9/–
–Other 0.3mg/L (0.2–0.4) – 1.63mg/L (1.3–2.1) 5.4/–
Citalopram 1 Fatal intoxication involving
topiramate
Blood: 0.85mg/L 7.3mg/L 8.6 [141]
Citalopram 1 Suicide by citalopram and
cyproheptadine intoxication
2.3mg/L – 9.0mg/L 3.9/– [142]
Clomipramine 1 Drug-related death Blood: 2.86mg/mL 19.70mg/mL 6.9 [126]
Clotiapine 4 –Acute mixed intoxication 110mg/L 75mg/L 657mg/L 6.0/8.8 [143]
–Not known 310mg/L – 1860mg/L 6.0/–
–Acute mixed intoxication 340mg/L 200mg/L 6320mg/L 19/32
–Not known 58mg/L 50mg/L 9120mg/L 157/182
Clozapine 1 Suicide by acute clozapine
overdose
8.8mg/L 12.0mg/L 1844mg/L 209/154 [144]
Clozapine 1 Suicide by multiple drug
intoxication
– 0.2mg/L NQ –/– [145]
Cocaine 4 Fatal intoxication involving
cocaine
Blood: 6.9mg/L 18.0mg/L 2.6 [146]
Blood: 3.9mg/L 8.2mg/L 2.1
Blood: 1.8mg/L 10.0mg/L 5.5
Blood: 13.0mg/L 25.0mg/L 1.9
Cocaine 1 Overdose fatality involving
cocaine
Blood: 330mg/L 25mg/L 0.07 [147]
Cocaine
(BZEa)







Cocaine 1 Overdose by cocaine Blood: 51.7mg/L 46.8mg/L 0.91 [149]
Cocaine 2 Overdose by cocaine Blood: 5mg/L 1.5mg/L 0.30 [150]
Blood: 1.6mg/L 2.0mg/L 1.3
Cocaine
(BZE; EMEa)













Cocaine 1 Fatal intoxication involving
cocaine
– – 0.75mg/mL –/– [57]
Codeine 1 Acute heroin fatality NA Embalmment 305ng/mL – [152]
Codeine 3 Multiple drug intoxication Blood: 17.2ng/mL (7.9–25) 55.5ng/mL
(19.4–80.1)
3.2 [114]
Codeine 1 Fatal intoxication involving
codeine
Whole Blood: 22.1mg/L 9.2mg/L 0.42 [153]









































Codeine 1 Multiple drug intoxication Right femoral vein: 0.33mg/L
Left femoral vein:
0.39mg/L
Thoracic: 0.49mg/L 0.84mg/L Right: 2.5
Left: 2.2/1.7
[117]
Colchicine 2 Suicidal colchicine poisoning 17.4ng/mL 5.2ng/mL 42.8ng/mL 2.5/8.2 [155]
21.9ng/mL 22.8ng/mL 1818.5ng/mL 83/80
Colchicine 1 Fatal accidental intoxication by
colchicine
– 50g/L 12,000mg/L –/240 [156]
Colchicine 1 Suicide by colchicine intoxication – 66ng/mL 5632ng/mL –/85 [157]
Colchicine 1 Accidental intoxication by
colchicine
Blood: ND 7.5mg/mL – [87]
Colchicine 1 Suicide by colchicine poisoning 62ng/mL – 2921ng/mL 47/– [86]
Cyproheptadine 1 Suicide by citalopram and
cyproheptadine intoxication
0.49mg/L – 30.7mg/L 62/– [142]
Cyproheptadine 1 Fatal intoxication involving
ethanol and cyproheptadine
0.47mg/L 0.62mg/L 8.1mg/L 17/13 [158]
Cytisine 1 Fatal intoxication involving
cytisine
2.5ng/mL 0.9ng/mL 6.1ng/mL 2.4/6.7 [159]
Desipramine 1 Multiple drug intoxication Blood: 4.2mg/L 23mg/L 5.5 [138]
Despropionyl
Bezitramide
1 Multiple drug intoxication Blood: 106.1ng/mL 621.5ng/mL 5.9 [160]
Dextromoramide 2 Fatal overdose involving
dextromoramide
– 871.1ng/mL 50.2ng/mL –/0.06 [161]
– 984.3ng/mL 175.0ng/mL –/0.17
Diﬂunisal 1 Fatal intoxication involving
diﬂunisal
Blood: 260mg/L 71mg/L 0.27 [162]
Digoxin 1 Fatal intoxication involving
digoxin and doxepin
Blood: 169ng/mL 4900ng/mL 29 [163]
Diltiazem 1 Acute intoxication involving
diltiazem and pentoxifylline and
cardiomyopathy
Blood: 0.59mg/dL 0.4mg/dL 0.68 [164]
Diltiazem 1 Fatal intoxication involving
diltiazem
Blood: 31.1mg/L 294.9mg/L 9.5 [165]













Diphenhydramine 1 Multiple drug intoxication Right femoral vein: 0.41mg/L
Left femoral vein:
0.45mg/L
Thoracic: 0.66mg/L 2.3mg/L Right: 5.6
Left: 5.1/3.5
[117]
Disopyramide 1 Accidental overdose of
disopyramide and sulindac
Blood: 41.3mg/L 435mg/L 10 [167]
Dizocilpine (MK-801) 1 Multiple drug intoxication Blood: 0.15mg/L 0.29mg/L 1.9 [168]
Dothiepin 1 Overdose by dothiepin Blood: 5.75mg/L 110mg/L 1.9 [169]
Doxacurium 1 Fatal intoxication of doxacurium – >LOD (10ng/mL) NQ > LOD (10ng/mL) NQ –/– [170]
Doxepin 1 Fatal intoxication involving
digoxin and doxepin
Blood: 1.8mg/L 15mg/L 8.3 [163]
Doxepin 7 – Acute fatal doxepin intoxication 780ng/mL 998ng/mL 110,924ng/mL 142/111 [171]
– Acute fatal doxepin intoxication 3786ng/mL 4111ng/mL 101,553ng/mL 27/25
– Multiple drug intoxication 113ng/mL 139ng/mL 1510ng/mL 13/11
– Multiple drug intoxication 34.4ng/mL 45.4ng/mL 778ng/mL 22/17
– Multiple drug intoxication 84.0ng/mL 106ng/mL 1220ng/mL 14/12
– Other 378ng/mL 549ng/mL 35,997ng/mL 95/66
– Unknown 41.4ng/mL 45.9ng/mL 1310ng/mL 31/28
Duloxetine 7 – Multiple drug intoxication 0.10mg/L 0.17mg/L 1.1mg/L 11/6.5 [172]
– Multiple drug intoxication 0.09mg/L 0.22mg/L 2.0mg/L 22/10
– Multiple drug intoxication – 0.28mg/L 1.3mg/L –/4.6
– Morphine intoxication – 0.22mg/L 1.3mg/L –/5.9
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Peripheral blood Cardiac blood
– Arteriosclerotic cardiovascular
disease
0.05mg/L 0.08mg/L 0.57mg/L 11/7.1
– Methadone intoxication 0.20mg/L 0.23mg/L 0.69mg/L 3.5/3.0
Ethyltryptamine 1 Fatal intoxication involving
ethyltryptamine
– 5.6mg/L 22.0mg/L –/3.9 [173]
Etomidate 3 – Suicide by etomidate
intoxication
0.40mg/L – 0.46mg/L 1.2/– [174]
– Medical intervention/Crush
injuries
0.05mg/L – 0.37mg/L 7.4/–
– Medical intervention/injury at
chest and abdomen
<0.026mg/L – 0.11mg/L –/–
Fentanyl 15 – Fatal intoxication involving
fentanyl
11.6mg/mL (4.5–18) 22.2mg/mL (3.5–55) 103.3mg/mL
(3.5–197)
8.9/4.7 [76]
– Other 11.2mg/mL (6.8–19) 17.9mg/mL (+<2.0–81) 57.7mg/mL
(5.9–262)
5.1/3.2
– Suicide by multiple drug
intoxication
– Embalmed 25mg/L –/–
Fentanyl 1 Overdose by fentanyl Blood: 27.5mg/L 58.2mg/L 2.1 [175]













Fentanyl 1 Fatal intoxication involving
fentanyl
Blood: 4.8mg/L 4.7mg/L 0.98 [177]
Fentanyl 1 Combined intoxication with
fentanyl and bromazepam
60.6mg/L 94.1mg/L 436.4mg/L 7.2/4.6 [178]
Fentanyl 1 Fatal intoxication involving
fentanyl
Blood: 4.9ng/mL 8.8ng/mL 1.8 [179]





Flecainide 1 Fatal intoxication involving
ﬂecainide
Blood: 13mg/L 160mg/L 12 [181]
Flecainide 1 Suicide by ﬂecainide intoxication Blood: 93.7mg/L 418.9mg/L 4.5 [182]
Flecainide 1 Multiple drug intoxication 7.7mg/kg – 0.26mg/kg 0.03/– [183]
Fluoxetine 8 Civil aviation accident Blood: 0.35mg/mL (0.021–0.682) 3.51mg/mL
(0.126–5.90)
10 [184]
Fluoxetine 1 Suicide by ﬂuoxetine intoxication Blood: 6000ng/mL 13,000ng/mL 2.2 [185]
Flurazepam 1 Suicide by acute ﬂurazepam
overdose
5.5mg/L – 33mg/L 6.0/– [186]
Flurazepam 1 Suicide by acute intoxication of
ﬂurazepam
– 2.8mg/mL 323mg/mL –/115 [187]
GHBa 1 Fatal intoxication GHB/Heroin 11.5mg/mL 57.0mg/mL 5.0 [188]
GHBa 1 Fatal overdose involving GHB 2937mg/L 3385mg/L 1800mg/L 0.61/0.53 [189]
Haloperidol 1 Suicide by multiple drug
intoxication
– 0.2mg/L NQ –/– [145]
Haloperidol 2 – Suicidal overdose by haloperidol Blood: 1.9mg/L 3.4mg/L 1.8 [190]
– Natural cardiac death Blood: 0.6mg/L 0.4mg/L 0.67
Halothane 2 – Homicide by forced halothane
inhalation
Blood: 7.2mg/kg 7.5mg/kg 1.0 [191]




























































Hydroxyzine 1 Suicide by overdose of hydroxyzine Blood: 39mg/L 122mg/L 3.1 [192]
Hydroxyzine 1 Fatal intoxication involving
hydroxyzine
Blood: 4.18mg/mL 23.24mg/mL 5.6 [193]
Ibogaine 1 Fatal poisoning involving ibogaine 5.41.4 ng/mL 6.60.6 ng/mL 21.35.6 ng/mL 3.9/3.2 [194]
Imipramine 1 Multiple drug intoxication Right femoral vein: 2.5mg/L
Left femoral vein: 2.3mg/L
Thoracic: 5.2mg/L 19mg/L Right:8.3/3.7
Left:7.6
[117]
Isoniazid 1 Fatal intoxication involving
isoniazid
94mg/L 43mg/L 900mg/L 9.6/21 [195]
Jesaconitine 1 Suicide by ingestion of aconite Serum: 69.1ng/mL 237.8ng/g # [120]
Ketamine 1 Homicide by ketamine
intoxication
Blood: 27.4mg/mL 15.2mg/mL 0.55 [196]
Lamotrigine 2 – Natural seizure disorder – 8.3mg/L 6.8mg/L –/0.82 [197]
– Fatal intoxication by lamotrigine 54mg/L 52mg/L 92mg/L 1.7/1.8
Levomepromazine 1 Drug-related death Blood: 0.01mg/mL 0.53mg/mL 53 [126]
Lidocaine 1 Cardiac ﬁbrillation Blood: 31mg/mL 6mg/mL 0.19 [198]
Lidocaine
MGEXa
5 Varied, requiring endotracheal
intubation (survival time at














Lithium 1 Mixed-drug intoxication involving
tranylcypromine and lithium
0.57mmol/L – 1.42mmol/L 2.5/– [200]
Lithium 1 Fatal intoxication involving
lithium
Blood: 1.93mequiv./L 15.7 mequiv./L 8.1 [201]
Loxapine 1 Suicide by acute loxapine overdose – 9.5mg/L 28.8mg/L –/3.0 [202]
Maprotiline 1 Suicide by drug intoxication 8.6mg/L 7.3mg/L 137mg/L 16/19 [203]
mCPPa 1 Ingestion of mCPP followed by
asthma attack that led to death
NA Embalmment 5.1ng/mL –/– [204]
mCPPa 1 Multiple drug intoxication Blood: 325.5mg/g 945.2mg/g 2.9 [205]
MDAa 1 Suicide by multiple drug
intoxication
Serum: 0.43mg/L – 0.82mg/L 1.9/– [206]
MDAa 11 – MDMA intoxication – 2.090mg/mL (0.026–10.083) 9.27mg/mL
(ND–36.447)
–/4.4 [79]
– Multiple drug intoxication – 0.484mg/mL (0.070–1.809) 1.385mg/mL
(0.161–5.522)
–/2.9
– Stab wound – 0.112mg/mL 0.378mg/mL –/3.4
MDA a 1 Intoxication by MDEAa overdose Serum: 0.32mg/L Serum: 0.34mg/L 0.44mg/kg #/# [207]
MDDM or MDDAa 1 MDMAa overdose 2.5ng/mL 21.7ng/mL 1101ng/mL 440/51 [208]
MDEAa 1 Suicide by multiple drug
intoxication
Serum: 7.3mg/L – 11.3mg/L 1.5/– [206]
MDEAa 1 Intoxication by MDEA overdose Serum: 12mg/L Serum: 22mg/L 19mg/kg #/# [207]
MDMAa 1 Fatal intoxication involving
MDMA
Blood: 2.9mg/L 73mg/L 25 [209]
MDMAa 1 Acute cardiopulmonary failure 3.1mg/mL 5.7mg/mL 14.2mg/mL 4.6/2.5 [210]
MDMAa 2 – Fatal hyperthermia – 0.420mg/mL 22.075mg/mL –/53 [211]
– Acute cardiopulmonary failure 13.508mg/mL – 86.954mg/mL 6.4/–
MDMAa 1 Overdose fatality involving 4-MTA
and MDMA
10.5mg/L 16.5mg/L 231.1mg/L 22/14 [113]
MDMAa 1 Suicide by multiple drug
intoxication
Serum: 13.3mg/L – 23.5mg/L 1.8/– [206]
MDMAa 11 – MDMA intoxication – 2.453mg/mL (ND-3.548) 4.467mg/mL
(ND-6.865)
–/1.8 [79]
– Multiple drug intoxication – 10.09mg/mL (1.301–40.41) 31.85mg/mL
(1.262–131.0)
–/3.2
– Stab wound – 1.630mg/mL 16.02mg/mL –/9.8










































Table 2 (Continued )






Peripheral blood Cardiac blood
MDPVa 1 Acute death from MDPV 0.44mg/mL 0.50mg/mL 0.88mg/mL 2.0/1.8 [212]
Mephedrone 1 Multiple drug intoxication Blood: 1.33mg/L 1.29mg/L 1.0 [213]
Methamphetamine 1 Suicide by methamphetamine
overdose
30mg/L – 17mg/L 0.57/– [129]
Methamphetamine 1 Ventricular ﬁbrillation/
tachycardia
Blood: 0.7mg/L 21.7mg/L 31 [214]
Methocarbamol 1 Fatal drug interaction caused by
ingestion of methocarbamol and
ethanol
Blood: 257mg/mL 927mg/mL 3.6 [215]
Methylone 3 Suicide by headshot
Drowning














Metoprolol 1 Suicide by acute metoprolol
overdose
Blood: 4.7mg/L 254mg/L 54 [217]
Metoprolol 1 Suicide by acute metoprolol
overdose
Blood: 19.8mg/L 83.1mg/L 4.2 [218]
Mexiletine 1 Suicide by acute mexiletine
overdose
14mg/L 38mg/L 440mg/L 31/12 [219]
Midazolam 1 Fatal intoxication involving
fentanyl
Blood: 7.5ng/mL 3.3ng/mL 0.4 [179]
Mirtazapine 7 Therapeutic use of mirtazapine 0.17mg/L (0.04–0.24) 0.19mg/L (0.03–0.32) 2.76mg/L
(0.40–6.6)
16/15 [220]
Mirtazapine 8 – Acute ethanol intoxication 0.07mg/L ND ND –/– [221]
– Acute alcohol intoxication <0.01mg/L <0.01mg/L ND –/–
– Narcotic intoxication 0.13mg/L 0.14mg/L 0.9mg/L 6.9/6.4
– Cocaine intoxication 0.13mg/L 0.14mg/L 1.6mg/L 12/11
– Narcotic and ethanol
intoxication
0.05mg/L 0.05mg/L 0.42mg/L 8.4/8.4
– Other 0.01mg/L (ND-0.01) 0.15mg/L(0.01–0.33) 0.18mg/L
(0.11 to 0.51)
18/1.2
Mirtazapine 1 Adverse effects of mirtazapine
initiated a process leading to death
1030ng/mL 380ng/mL 2950ng/mL 2.9/7.8 [222]
Molidone 1 Multidrug overdose Blood: 6mg/L 23mg/L 3.8 [223]
Morphine 1 Acute heroin fatality NA Embalmment 2476ng/mL –/– [152]
Morphine 3 Not speciﬁed Blood: trace 7.6mg/100g –/– [224]
Blood: trace 9.0mg/100g –/–
Blood: 0.4mg/100g 14.5mg/100g 36
Morphine 3 Multiple drug intoxication Blood: 140.4ng/mL (60.5–250.7) 33,018ng/mL
(1211.1–78,906.5)
236 [114]





Morphine 1 Accidental poisoning by morphine Blood: 0.128mg/L 135mg/L 1054 [225]
Morphine 1 Heroin overdose Blood: ND (death 6 days after intoxication) 21.3mg/mL –/– [84]
Morphine 1 Possible overdose by heroin 168mg/L – 357mg/L 2.1/– [154]
Morphine 1 Fatal intoxication GHB/Heroin 0.77mg/mL 14.3mg/mL 19 [188]
Morphine 1 Fatal intoxication involving heroin
and ethanol
Blood: 0.68mg/mL 0.32mg/mL 0.47 [226]
Morphine 37 – Heroin related death
With cocaine or metabolite
>0.01mg/L (n=8)
Total morphine: 0.33mg/L (0.12–1.10)




– Heroin related death
Without cocaine or metabolite
<0.01mg/L (n=29)
Total morphine: 1.13mg/L (0.07–5.00)


























































Olanzapine 1 Hypertensive cardiovascular
disease
– 550ng/mL 6346ng/mL –/12 [229]
Orphenadrine 12 – Fatal intoxication involving
orphenadrine
Blood: 21.2mg/mL (5.5–37) 150mg/mL (85–234) 7.1 [230]
– Multiple drug intoxication Blood: 14.6mg/mL (0.04–55) 106.1mg/mL
(0.04–270)
7.3
Oxycodone 15 – Multiple drug intoxication 0.92mg/L (0.19–2.2) 0.84mg/L (0.12–1.9) 5.69mg/L (0.19–23) 6.2/6.8 [77]
– Suicide by multiple drug
intoxication





1 Fatal poisoning with Taxus
baccata
















Pancuronium 1 Fatal intoxication involving
pancuronium
0.7mg/L 0.7mg/L 0.4mg/L 0.57/0.57 [233]
Pentobarbital 1 Suicide by acute pentobarbital
overdose
13.5mg/mL – 67.4mg/mL 5.0/– [234]
Pentoxifylline 1 Acute intoxication involving
diltiazem and pentoxifylline and
cardiomyopathy
Blood: 0.63mg/dL 0.22mg/dL 0.35 [164]
Perphenazine 1 Suicide by multiple drug
intoxication
3.5mg/L 4.4mg/L 40mg/L 11/9.1 [145]
Phendimetrazine 1 Fatal intoxication involving
phendimetrazine
Blood: 0.67mg/mL 2.03mg/mL 3.0 [235]
Phenobarbital 1 Drug-related death Blood: 15mg/mL 36.80mg/mL 2.5 [126]
Piritramide 1 Fatal piritramide overdose 0.1mg/L 0.32mg/L 2.51mg/L 25/7.8 [236]
Platinium (Cisplatin) 1 Fatal accidental cisplatin overdose 1213mg/L 1515mg/L 501mg/L 0.41/0.33 [237]
Pregabalin 11 – Multiple drug intoxication 22.6mg/L (5.6–45.3) 27.1mg/L (4.7–49.4) 61.2mg/L (12.2–159.4) 2.7/2.3 [238]
– Other 10.5mg/L (3.8–6.7) 4.2mg/L (3.8–4.6) 17.6mg/L (17.0–18.2) 1.7/4.2
– Not reported 8.78mg/L (4.4–16.3) 6.6mg/L (2.7–11.1) 16.9mg/L (10.5–19.7) 1.9/2.6
Propofol 1 Accidental tramadol and propofol
intoxication
– 0.2mg/mL 0.71mg/mL –/3.6 [239]
Propoxyphene 3 Suicidal poisoning with co-
proxamol
4.6mg/L 14mg/L 34mg/L 7.4/2.4 [118]
3.2mg/L 8.7mg/L 48mg/L 15/5.5
3.9mg/L 4.2mg/L 37mg/L 9.5/8.8
Quazepam 1 Ischemic heart disease Total: 17.7 1.2 ng/mL
Free: 18.6 1.3 ng/mL
Total: 17.5 1.2 ng/mL
Free: 19.3 0.8ng/mL
Total: 24.1 1.8 ng/mL




Quetiapine 4 – Acute myocardial ischemia due
to coronary artery atherosclerosis
1.0mg/L – 6.0mg/L 6.0/– [241]
– Acute combined ethanol and
quetiapine poisoning
6.0mg/L – 33mg/L 5.5/–
– Suicide by quetiapine overdose 1.0mg/L – 40mg/L 40/–
– Fatal mixed-drug overdose – 11mg/L 96g/L –/8.7
Quetiapine 3 – Multiple drug intoxication 0.95mg/L 5.1mg/L 7.5mg/L 7.9/1.5 [242]
– Multiple drug intoxication 0.26mg/L 0.43mg/L 1.3mg/L 5.0/3.0
– Fatal cocaine intoxication <0.10mg/L <0.10mg/L 0.60mg/L –/–
Quetiapine 5 – Multiple drug intoxication Blood: 19.8mg/L 161.5mg/L 8.2 [243]
– Multiple drug intoxication Blood: 2.7mg/L 46.2mg/L 17
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Peripheral blood Cardiac blood
– Other Blood: 0.15mg/L 10.1mg/L 67
– Other Blood: 2.7mg/L 16.5mg/L 6.1
Rifampicin 1 Fatal overdose by rifampicin Blood: 552mg/mL 3132mg/mL 5.7 [244]
Ropinirole 1 Fatal intoxication involving
ropinirole
64ng/mL – 826ng/mL 13/– [245]





Sertraline 1 Adverse effects of mirtazapine
initiated a process leading to death
880ng/mL – 52,170ng/mL 59/– [222]
Sildenaﬁl 1 Fatal sildenaﬁl-verapamil
intoxication
Blood: 105ng/mL 1206ng/mL 12 [247]
Sildenaﬁl 1 Heart failure due to
myocardiosclerosis
Blood: 0.04mg/L 0.99mg/L 25 [248]
Strychnine 1 Acute strychnine poisoning – 2.40mg/L –/– [249]
Strychnine 1 Suicide by rodenticide poisoning 0.96mg/L 0.31mg/L 1.17mg/L 12/3.8 [250]
Strychnine 1 Fatal poisoning of strychnine 1.82mg/L 3.32mg/L 11.4mg/L 6.3/3.4 [251]
Strychnine 1 Fatal intoxication involving
strychnine
Blood: 3.3mg/L 9.2mg/L 2.8 [252]
Sulindac 1 Accidental disopyramide and
sulindac overdose
Blood: 12.2mg/L 1251mg/L 102 [167]
Tetrahydrophtalimide 1 Multiple drug intoxication 0.22mg/mL 0.35mg/mL 0.30mg/mL 1.4/0.86 [253]







Theophylline 1 Fatal intoxication involving
theophylline
Blood: 250mg/L 275mg/L 1.1 [254]
Thiamylal 1 Hanging Blood: 29mg/L 16mg/L 0.55 [255]
Thiamylal 1 Fatal intoxication involving
thiamylal
Blood: 129mg/L ND – [256]
Thioridazine (TRZ) 1 Fatal intoxication involving
thioridazine











Tilidine 1 Multiple drug intoxication and
long exposure at cold temperature
Blood: 1.74mg/L 2.88mg/L 1.7 [258]
Tioridazine 1 Drug-related death Blood: 2.06mg/mL 1.62mg/mL 0.79 [126]
Tizanidine 1 Suicide by multiple drug
intoxication
– 2.34mg/L 3.37mg/L –/1.4 [259]
Topiramate 1 Seizure disorder with upper
respiratory infection
Blood: 8.9mg/L 10.9mg/L 1.2 [260]
Topiramate 1 Fatal intoxication involving
topiramate
Blood: 49mg/L 48mg/L 0.98 [141]
Tramadol 1 Severe depression of fundamental
function as consequence of acute
intoxication of tramadol
61.83mg/mL – 107.94mg/mL 1.7/– [261]
Tramadol 1 Accidental intoxication with
tramadol and propofol
– 5.3mg/mL 15mg/mL –/2.8 [239]
Tramadol 1 Fatal tramadol intoxication 9.6mg/L 13.1mg/L 46.1mg/L 4.8/3.5 [262]
Tranylcypromine 1 Mixed-drug intoxication involving
tranylcypromine and lithium
0.19mg/mL – 0.35mg/mL 1.8/– [200]



















































Trimetazidine 1 Fatal sildenaﬁl-verapamil
intoxication
Blood: 2133ng/mL 553ng/mL 0.26 [247]
Valproic acid 1 Fatal intoxication involving
valproic acid
Blood: 1050mg/mL 713mg/mL 0.68 [264]
Vardenaﬁl 1 Fatal aviation accident – 291ng/mL 1665ng/mL –/5.7 [265]
Venlafaxine 9 – Suicide by venlafaxine overdose
(combined drug toxicity)
7.2mg/L – 10.6mg/L 1.5/– [266]
– Suicide by venlafaxine overdose
(combined drug toxicity)
31mg/L – 46mg/L 1.5/–
– Suicide by venlafaxine overdose
(combined drug toxicity)
36mg/L – 53mg/L 1.5/–
– Other 1.7mg/L (0.1–6.6) – 5.02mg/L
(<0.05–20)
3.0/–
Venlafaxine 1 Suicide by mixed-drug
intoxication
6.2mg/L – 54mg/L 8.7/– [267]
Venlafaxine 2 – Suicide by acute venlafaxine
overdose
– 6.4mg/L 100mg/L –/16 [268]
– 84mg/L 290mg/L –/3.5
Verapamil 1 Overdose by verapamil Blood: 16.5mg/L 62.6mg/L 3.8 [269]
Verapamil 1 Fatal sildenaﬁl-verapamil
combination
Blood: 659ng/mL 3129ng/mL 4.7 [247]
Xylazine 1 Hanging 6.3mg/L 2.9mg/L 0.01mg/L 0.02/0.03 [270]
Zaleplon 3 – Suicide by multiple drug
intoxication
<3.0ng/mL 13ng/mL <3.0ng/mL –/– [271]
– Pulmonary thromboembolism – 55ng/mL 85ng/mL –/1.5
– Drowning/Effect of multiple drug
intoxication
503ng/mL 227ng/mL 33ng/mL 0.07/0.15
Zaleplon 1 Multiple drug intoxication – 2.2mg/L 8.6mg/L –/3.9 [272]





Zipeprol 1 Fatal overdose involving zipeprol – 6.69mg/L 55.56mg/L –/8.3 [274]
Zolpidem 2 Suicide by zolpidem overdose Blood (subclavian) =4.5mg/L; (iliac) =7.7mg/L 8.9mg/L Subclavian:2.0
Iliac:1.2
[275]
Blood (iliac) =1.6mg/L 2.6mg/L 1.6
Zolpidem 1 Suicide by zolpidem overdose Blood: 3.29mg/L 1.27mg/L 0.39 [116]
Zopiclone 1 Suicide by zopiclone overdose 254ng/mL 408ng/mL 114,700ng/mL 451/281 [276]
Zopiclone 1 Fatal intoxication involving
zopiclone
Left femoral vein: 1.2mg/mL Superior vena
cava: 1.4mg/mL
14.1mg/mL 12/10 [277]
ND, not detected; NQ, detected but Not Quantiﬁed; # ratio not calculated because units of blood and bile values are not the same.
a 4-MTA, 4-methylthioamphetamine; 6MAM, 6-monoacetyl-moprhine; AH-7921, 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide; BZE, benzoylecgonine; EME, ecgonine-methylester, DMT, dimethyltrypta-
mine; GHB, gamma-hydrxybutyric acid; mCPP, meta-Chlorophenylpiperazine; MDA, 3,4-methylendioxyamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDEA, 3,4-methylenedioxyethylamphetamine; MDDM or
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longer detection window in bile, making it interesting for the
detection of short half-life molecules in cases with long intake-to-
death interval, as may be the case with heroin [83,84] (6-
monoacetyl-morphine (6MAM) half-life = 6–25 min, morphine
half-life = 2–3 h [85]) and colchicine (half-life = 20 min) [86,87].
Thus, as several authors claim [16,17,78,80], bile may be the matrix
of choice for drug of abuse screening when blood concentrations
are low or non-detectable (weak exposure or long intake-to-death
interval) or blood is not available.
Bile has also been recommended as a complementary matrix to
blood for general unknown screening. In an autopsy series (n = 5),
Moriya et al. [88] highlighted the qualitative interest of bile, as
concentrations of 8 molecules were systematically higher than in
blood (mean bile/blood ratio, 5.74). In a series of 44 autopsies,
Vanbinst et al. [17] compared bile and blood concentrations for 26
medicines or their metabolites: bile/cranial blood ratios ranged
from 1,08 (paracetamol) to 1.944 (desclobazam). A brief review of
the literature entitled ‘‘Signiﬁcance of bile analysis in drug-
induced death’’ [16] cited several case reports to show that routine
bile analysis would be useful, as concentrations for most molecules
are signiﬁcantly higher than in blood; even when no molecules are
detected in blood, toxicology results should not be considered
negative without complementary bile analysis. As bile contains a
large proportion of metabolites, as in the case of cocaine,
nitrobenzodiazepines or THC [57,64,89], it is useful to include
metabolites in the screening.
However, molecules detected in blood may in some cases go
undetected in bile. In the study by Vanbinst et al. [17], in 6 cases
out of 44 (13.6%), molecules found in blood (clobazam, cocaine,
codeine, 3,4-methylendioxyamphetamine (MDA), northiaden, 7-
acetamidoﬂunitrazepam) were not detected in bile. Many hypoth-
eses were put forward but not discussed, one of the most
interesting being rapid death. The analytic method may be more
sensitive in blood than in bile. In one study, meprobamate was
quantiﬁed in blood but not bile in 13 cases out of 124 [90]:
quantiﬁcation limits for blood and bile were respectively 2.0 and
5.9 mg/mL.
4.3. Quantitative interpretation
4.3.1. Medical drugs and drugs of abuse
Quantitative interpretation of bile concentrations has been
rarely reported. Fernandez et al. [57] found poor correlation
(r = 0.48) between blood and bile concentrations of cocaine
derivatives in 20 cases, with bile/blood ratio ranging from 2.15
to 107.53. One limitation of their study was the use of a
radioimmunoassay (RIA) which failed to distinguish between
cocaine and its metabolites. In another study [88], of 5 autopsy
cases, there was no signiﬁcant correlation between bile and blood
concentrations for 8 substances taken together (diazepam,
atropine, lidocaine, ephedrine, norephedrine, methamphetamine,
amitriptyline, nortriptyline). The limitation of this study was the
small number of cases (n = 5), obliging the authors to combine the
8 neutral or alkaline molecules despite the fact that they showed
widely different bile/blood ratios (between 1.83 and 23.5).
A 19-case series compared blood and bile concentrations of
nitrobenzodiazepines (nitrazepam, ﬂunitrazepam, clonazepam)
and their 7-amino metabolites [89]. Correlation coefﬁcients were
0.695 for parent molecules and 0.829 for metabolites. The study
also included other alternative matrices (vitreous humor, liver and
urine), and concluded that the correlation was ‘‘encouraging’’ for
improving quantitative interpretation of nitrobenzodiazepine-
positive cases by analyzing several matrices postmortem. In a
series of 124 autopsies, meprobamate was analyzed simultaneous-
ly in blood and bile and a number of statistical models were appliedto help in interpreting the bile concentrations [90]. A signiﬁcant
correlation emerged (r = 0.66) despite a certain scatter when blood
concentration was higher than 100 mg/L. Secondly, two groups
were distinguished according to therapeutic (<50 mg/L) versus
supratherapeutic blood levels (>50 mg/L). A bile concentration
threshold of 53 mg/L was statistically equivalent to the blood
concentration threshold of 50 mg/L, with 0.95 sensitivity and 0.93
speciﬁcity in this population.
Bevalot et al. [91] combined an animal experiment with a series
of autopsy cases on 6 test substances (meprobamate, morphine,
cyamemazine, caffeine, diazepam, and citalopram) to assess both
qualitatively and quantitatively the use of bile as alternative
matrix to blood. The concentrations of these 6 substances were
determined by GC/MS-MS in rabbit specimens collected at various
delays between injection and euthanasia and in human postmor-
tem samples. Qualitative interest of bile analysis was indisputable
as all molecules detected in blood were found in bile. Moreover
animal experiment demonstrated a wider time detection window
for bile than blood. Quantitative interpretation was limited for
molecules with the highest bile/blood concentrations ratios
(morphine, citalopram, cyamemazine) as a poor correlation was
observed. Diazepam showed excellent correlation in bile speci-
mens from rabbits (r = 0.961, n = 20) but a poor correlation in
human postmortem cases (r = 0.447, n = 23). Remarkably, for
molecules with low bile/blood concentrations ratios (closed to 1):
cyamemazine and meprobamate, correlation between these two
matrices were signiﬁcant. However, due to non-negligible scatter,
the authors advised to infer blood concentrations from bile ones
with caution or using a statistical approaches which allows
estimation of uncertainty.
4.3.2. Gamma-hydroxybutyric acid
Due to the difﬁculty of interpreting postmortem blood
concentrations of gamma-hydroxybutyric acid (GHB), comple-
mentary alternative matrices have been used to distinguish
endogenous origin or postmortem neoformation from exogenous
input [92]. The two studies published concerning bile in this
context reported divergent results. Moriya [93] selected cases in
which inquest data ruled out exogenous input of GHB or gamma-
butyrolactone (GBL) and in which the postmortem interval was not
greater than 48 h (in order to limit the likelihood of postmortem
neoformation). For the 9 cases studied, bile concentrations were
homogeneous and low (from <LOD (0.5 mg/mL) to 2.8 mg/mL). The
author considered bile to be an alternative matrix of choice as
endogenous GHB levels are low and suggested a 10 mg/L bile
threshold to distinguish endogenous versus exogenous GHB. Kintz
et al. [94] examined 14 cases in which exogenous exposure to GHB
was unlikely but where cardiac blood concentrations were above
the 50 mg/L threshold consistent with endogenous formation. For
these 14 cases, femoral blood and vitreous humor concentrations
were below the 50 mg/L threshold, whereas bile concentrations
displayed wide scatter (6.1–238 mg/L, n = 7). In this second study,
the authors concluded that bile did not meet the prerequisites for
interpreting GHB concentrations.
4.3.3. Ethanol
Many studies have focused on interpreting ethanol concentra-
tions in alternative matrices when no blood is available or to
conﬁrm a high blood concentration thought to be due to
postmortem redistribution or neoformation. Kugelberg et al.’s
review [95] of the interpretation of ethanol analyses merely
mentions bile as being one of the non-conventional samples.
Nevertheless, it was the focus of numerous reports, especially in
the 1980s and early 1990s. Thus, bile ethanol concentration
correlated strongly with blood ethanol (r = 0.927, n = 37 [96];
r = 0.9107, n = 189 [97]; r = 0.94, n = 100 [98]); mean bile/blood
Table 3
Bile/blood ethanol concentration ratios in the literature.
Ref. Number of cases Bile/blood ethanol concentration ratio
Mean SD Range
[99] 78 [ethanol] = 0.02 a` 0.49% 0.92 0.22 –
[96] 37 1.00 0.19 0.45–1.45
[97] 189 1.03 0.29 0.32–2.91
[97] 129 Bile concentration weighted for lipid content 1.00 0.29 0.40–2.58
[101] 5 – – 0.7–1.12
[98] 100 1.1 0.3 0.8–1.4
Cited in [42] – – – 0.7–1.4
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concentrations from bile requires caution: the studies as a whole
showed wide scatter for bile concentrations as seen from the wide
range of bile/blood ratios (Table 3). Stone and Rooney [99] reported
greater ratio variation for ethanol concentrations less than 0.1%
(CV = 34%) compared to concentrations higher than 0.1% (CV 14%;
data corrected in a letter to the editor [100]). Winek et al. [97]
showed that scatter was reduced if bile ethanol concentration was
corrected for sample lipid content. Intake-to-death interval may
also account for the scatter: Christopoulos et al. [101], in an 8-case
series, reported bile concentrations to be higher than in blood in
deaths rapidly following massive alcohol intake (<15 min, n = 3)
and lower in slower death. Taken together, these ﬁndings show
that, despite signiﬁcant correlation between the two matrices,
blood concentration is hard to extrapolate from bile data alone.
Winek et al. [97] described an approach taking account of this
uncertainty, reporting bile extrapolation as estimated blood
concentration ranges with associated uncertainty values.
In plane accidents or in explosions in which body damage is
often extreme, negative ﬁndings in bile or other matrices (urine,
brain, kidney, etc.) help in demonstrating postmortem ethanol
neoformation suspected in certain positive blood samples
[102,103]. On the other hand, in a study of ethanol analysis in
decomposed cadavers [104], postmortem neoformation was
suspected in 55 cases: ethanol was detected in blood and in bile
whereas ethanol levels in urine and vitreous humor remained low
or equal to zero. Thus, as in any biological sample, bacterial
contamination may induce ethanol production in bile. Bile, when
available, can be used to screen for ethanol to distinguish
neoformation from antemortem consumption of alcohol, associat-
ed to analysis of other biological ﬂuids and study of circumstances
of death. Screening for ethylglucuronide, a minor ethanol
metabolite, is often useful in this problematic: one study showed
ethylglucuronide to be strongly excreted into bile, with concen-
trations higher than in blood [105].
4.4. Postmortem redistribution
Gallbladder bile has been studied both as a possible source of
postmortem redistribution due to high xenobiotic content and as a
target for molecule diffusion from anatomically close abdominal
organs.
Postmortem redistribution was studied in rabbit according to
euthanasia-to-sampling interval following intravenous adminis-
tration of 3 beta-blockers (n = 18, interval: 0–48 h) [106] and of
MDMA (n = 15; interval: 0–72 h) [107]. Both studies focused on
bile concentration evolution, ﬁnding reduction with postmortem
interval. In both studies, bile concentrations were higher than in
the liver and xenobiotic diffusion from bile to liver may have
contributed to the postmortem increase in liver concentration. For
beta-blockers, the reduction in bile concentration may have
contributed to a concomitant non-signiﬁcant increase in periph-
eral blood concentration in the inferior vena cava. Finally, bilerelease into the duodenum and then in the stomach could partially
account for early detection of beta-blockers in the stomach despite
administration having been intravenous according to the authors.
This hypothesis of duodenal-gastric reﬂux of bile was put forward
in a study focusing on gastric morphine concentrations in
intravenous heroin overdose [73]. Another study focused on
postmortem redistribution of THC in pig (n = 15) [108] after
intrajugular administration, with postmortem intervals of 0–48 h;
bile and liver concentrations seemed not to vary with postmortem
interval, but signiﬁcant ﬁndings were prevented by the low
concentrations found, which were the lowest of all the tissues
studied (bile, 1.4–7.5 ng/g; right liver, 2.8–8.2 ng/g; left liver,
4.0–8.0 ng/g).
The stomach has been studied as a possible source of
postmortem redistribution. It may constitute a reservoir of
xenobiotics if absorption was incomplete at time of death. De
Letter et al. [109] simulated this by postmortem infusion of MDMA
into the stomach or trachea (to simulate gastro-esophageal reﬂux)
in rabbit. Pounder et al. studied the hypothesis by postmortem
instillation of a medical drug cocktail (amitriptyline, paracetamol,
lithium) in human cadaver [110] and 8 cases of medical drug
overdose. Taken together, these results showed diffusion from the
stomach toward the left liver, generally sparing the right lobe. Only
Pounder et al. [110] focused on bile concentrations, reporting
diffusion to the gallbladder, although less than to the liver.
Finally, few signiﬁcant studies of postmortem redistribution
have focused on bile. These studies, cited above, disclosed a
tendency for levels to diminish over time due to xenobiotic
diffusion toward neighboring tissue with lower concentrations and
a mild contamination of the gallbladder by the stomach in case of
massive storage of xenobiotics in the stomach contents during the
absorption phase.
5. Conclusion
Postmortem forensic toxicological investigation aims to assess
xenobiotic intake and its relation to cause of death. Compound
detection in a biological matrix enables the ﬁrst, qualitative, level
of interpretation. Interpreting concentrations in terms of effect
(therapeutic, toxic, impaired vigilance, etc.) is the quantitative
aspect, and generally based on blood concentration interpretation.
The present review of the literature sought to update the ﬁeld of
knowledge as it can be applied to the use of the bile matrix in
forensic toxicology. Gallbladder bile is an additional autopsic
sample for analysis alongside other matrices (blood, stomach
contents, etc.) or when no analyzable blood sample is available.
Postmortem bile sampling is easy to perform at autopsy; the
essential factors to consider may be the fullness and postmortem
evolution of the gallbladder. Data are sparse on bile storage and
xenobiotic stability in bile, and the precautions recommended for
any biological sample are applicable with respect to use of
preservative agents and storage temperature. Certain authors have
suggested that bile, due to its composition (bile salts, etc.) and
F. Be´valot et al. / Forensic Science International 259 (2016) 133–154150alkaline pH, is not a favorable medium for bacteria, although
bacterial neoformation of ethanol in bile have been reported. Many
sample pretreatment and analytic techniques have been described
for bile analysis. The speciﬁc composition of bile may lead to
interferences and matrix effects, and it is important to bear these in
mind in developing an analytic method in order to ensure the
reliability of detection and measurement.
Biliary excretion is a complex process. It should be stressed that
knowledge of the biliary route is poorer than for other matrices
such as urine or blood, especially for compounds of forensic
interest, as in vivo access is obviously limited. Biliary excretion
appears to be strongly molecule-dependent, particularly with
respect to molecular weight, lipophilicity and afﬁnity toward
hepatocyte membrane transporters, and is based on active
processes. This general knowledge, added to a large number of
case reports and a few autopsy series, suggests that bile
concentrations are often greater than in blood and that the
concentration ratio may be very high. Bile has therefore been
suggested as matrix of choice for screening of medicines and of
drugs of abuse. The detection window for molecules signiﬁcantly
excreted in bile is longer than in blood if an equally effective
analytic method is performed, notably in terms of detection limits.
This may be of special interest for molecules with short half-life
when the intake-to-death interval is long (hospitalization, coma,
cranial trauma, etc.), as widely reported in the literature for opiates
and colchicine. Despite these qualitative advantages, bile is
generally used for screening only when urine, which is an
elimination medium easier to analyze, is absent.
There has been little research on bile for the quantitative
interpretation of xenobiotic concentrations. Even so, signiﬁcant
correlation has been demonstrated between bile and blood
concentrations for certain xenobiotics. Thus quantitative interpre-
tation of bile data is conceivable in the absence of any analyzable
blood. However, the wide scatter of concentrations in bile, as in
many other alternative matrices, requires tools to be developed
taking this uncertainty into account. Determining a bile threshold
for overdose [90] or a concentration range corresponding with a
known probability to the concentration measured in bile [97] have
been suggested. Finally, interpretation should also take account of
possible postmortem redistribution.
In conclusion, the present review of the literature highlights
not only the qualitative interest of bile but also a possible
quantitative interest in the case of several molecules. There are
gaps in our knowledge of bile excretion, and a lack of robust
studies of the interest, limitations and implementation of bile
analysis in forensic toxicology. Excretion mechanisms play a
determining role in the interpretation of bile analysis results.
From the qualitative point of view, it would be very useful to
know, or even predict, which molecules of forensic interest are
strongly secreted, and thus easily detected, in bile. Better
knowledge of hepatocytic active transport and its substrates is
needed. From the quantitative point of view, correlations between
blood and bile concentrations have been demonstrated for several
molecules. These seem to show certain common features: ethanol,
meprobamate, cyamemazine and, to a lesser degree, nitrobenzo-
diazepines, are all small molecules with low bile/blood concen-
tration ratios. It would thus be interesting to describe the
properties of molecules and the biliary excretion or reabsorption
mechanisms underlying these correlations.
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